Citadel Advisors’s Amryt Pharma AMYT Stock Holding History
Bought
Maintained
Sold
Other funds holding AMYT
Citadel Advisors's AMYT Position: Q1 2023 in Review
Citadel Advisors sold out of Amryt Pharma (AMYT) in Q1 2023, closing a stake of 41,280 shares — an estimated $301K sold.
Citadel Advisors first reported a position in AMYT in Q2 2021 and held it in 7 quarters. The position peaked at $640K in Q2 2022. 79 funds tracked by Wall St. Rank hold AMYT as of Q1 2023.
- Citadel Advisors reported no remaining Amryt Pharma position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 41,280 Amryt Pharma shares in Q1 2023, an estimated $301K.
- Citadel Advisors first reported a position in Amryt Pharma in Q2 2021 and held it in 7 quarters.
- Citadel Advisors's Amryt Pharma position peaked at $640K in Q2 2022.
- 79 funds tracked by Wall St. Rank held Amryt Pharma as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.